MINtS lung cancer multi-3CDx(Reference information available)

TOP
gene-related test
genetic tests for malignant tumor (solid tumor)
MINtS lung cancer multi-3CDx
(Reference information available)

Laboratory：Akiruno

○MINtS lung cancer multi-3CDx
(Reference information available)

CODE：00E28 6

TEST NAME SPECIMEN
REQUIREMENT
（ｍL） CONTAINER CAP COLOR STORE
TEMPERATURE
(STABILITY) TURNAROUND
TIME (DAY) METHODOLOGY REFERENCE RANGE
(UNIT)
MINtS lung cancer multi-3CDx
(Reference information available)
Unstained specimen slide
and
HE stained slide

10 sheets, thickness 5μm
and
1 sheet
Z10
13-20 Next Generation Sequencing (NGS)
A method that uses a next-generation sequencer to simultaneously determine the base sequences of a huge number of DNA fragments.

TEST NAME	SPECIMEN REQUIREMENT （ｍL）	CONTAINER
MINtS lung cancer multi-3CDx (Reference information available)	Unstained specimen slide and HE stained slide 10 sheets, thickness 5μm and 1 sheet	Z10

CAP COLOR	STORE TEMPERATURE (STABILITY)	TURNAROUND TIME (DAY)
		13-20

METHODOLOGY	REFERENCE RANGE (UNIT)
Next Generation Sequencing (NGS) A method that uses a next-generation sequencer to simultaneously determine the base sequences of a huge number of DNA fragments.

COMMENT

The purpose of this test is to detectEGFR gene mutations, ALK fusion genes, and BRAF gene V600E mutations using nucleic acids extracted from cancer tissue, and to determine the suitability of drugs for non-small cell lung cancer. We will also report the analysis results, which have not been approved by pharmaceutical regulations, for research purposes only.
The recommended percentage of tumor cells required for testing is 10% or more.
When submitting samples, please follow the detailed sample submission information provided in the ”Cytology Sample Collection and Processing Operation Manual” issued by EIKEN CHEMICAL CO.,LTD.
Please see below for points to note when submitting unstained specimen slides. When submitting unstained specimen slides, please be sure to also submit one HE-stained specimen with the tumor cell area marked.
Please avoid cryopreservation.
Please avoid requests that overlap with other items. This testing method is more susceptible to contamination, so please be careful when handling samples.
●When requesting this test
Please submit the sample according to the sample submission method described in the following document issued by EIKEN CHEMICAL CO.,LTD. for each test material. https://mints.eiken.co.jp/
-Cytological sample collection and processing operation manual
-Quality of cytological samples (guideline for total nucleic acid yield and sample appearance)
-How to submit bronchoscope cytodiagnosis samples
-How to submit pleural effusion samples for carcinomatous pleurisy
-How to submit FFPE samples

CONTAINER

Z10 Previous container symbol t

[Object cases] Preparation (slide glass)

Storage method: Room temperature

supplementary information

遺伝子変異等	がん腫	関連する医薬品
EGFR遺伝子変異	非小細胞肺癌	ゲフィチニブ、エルロチニブ塩酸塩、アファチニブマレイン酸塩、オシメルチニブメシル酸塩、ダコミチニブ水和物
ALK融合遺伝子	アレクチニブ塩酸塩、クリゾチニブ、ブリグチニブ、セリチニブ、ロルラチニブ
BRAF遺伝子V600E変異	ダブラフェニブメシル酸塩及びトラメチニブジメチルスルホキシド付加物の併用投与

Drugs related to target gene mutations and applicable cancers

Gene Mutations, etc.	Cancer	Related Drugs
EGFR gene mutation	non-small cell lung cancer	Gefitinib, Erlotinib hydrochloride, Afatinib maleate, Osimertinib mesylate, Dacomitinib hydrate
ALK fusion gene		Alectinib Hydrochloride, Crizotinib, Brigatinib, Ceritinib, Lorlatinib
BRAF gene (V600E mutation)		Coadministration of Dabrafenib mesilate and Trametinib dimethyl sulfoxide

TEST DIRECTORY